• PDB44 - THE HEALTH ECONOMIC VALUE OF SHORT-TERM CARDIOVASCULAR BENEFITS ASSOCIATED WITH SGLT-2I FROM CVD-REAL

    Oct 1, 2018, 00:00

  • PSY208 - PATIENTS’ PREFERENCES FOR PSORIASIS TREATMENT BASED ON A DISCRETE CHOICE EXPERIMENT. COEPSO STUDY

    Oct 1, 2018, 00:00

  • PMD161 - CLINICAL IMPACT OF A PHARMACEUTICAL PROFESIONAL SERVICE INTERVENTION WITH OR WITHOUT A MULTI-COMPARTMENT MEDICATION IN NON-ADHERENT, UNCONTROLLED, CHRONIC HYPERTENSIVE, POLYMEDICATED PATIENTS IN SPANISH COMMUNITY PHARMACIES. SEFAC- ...

    Oct 1, 2018, 00:00

  • PSY2 - IDENTIFICATION OF POTENTIAL BIAS FROM DATA SOURCES AND STUDY DESIGNS USED TO ESTIMATE PLATELET TRANSFUSION ADVERSE EVENT RATES

    Oct 1, 2018, 00:00

  • PCV32 - TRENDS IN THE INPATIENT CARE OF CORONARY HEART DISEASE IN 2005-2015

    Oct 1, 2018, 00:00

  • PMU111 - BEST PRACTICE METHODS AND CONSIDERATIONS FOR THE DEVELOPMENT, EVALUATION, AND IMPLEMENTATION OF INTERVIEWER-ADMINISTERED PATIENT-REPORTED OUTCOMES (ADPROS)

    Oct 1, 2018, 00:00

  • PCN152 - COST EFFECTIVENESS OF ALECTINIB IN THE FIRST LINE TREATMENT OF ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN TURKEY

    Oct 1, 2018, 00:00

  • PIH32 - INNOVATIVE PAYMENT MECHANISM- SOLVING INEQUITIES FOR HER2 (-) BREAST CANCER CASES IN CHILE.

    Oct 1, 2018, 00:00

  • PHP359 - IMPACT OF EXPEDITED MARKETING AUTHORISATION ON PRICING AND REIMBURSEMENT OUTCOMES FOR DRUGS IN THE US AND EU-5

    Oct 1, 2018, 00:00

  • PMD128 - ECONOMIC AND CLINICAL OUTCOMES AMONG PATIENTS WITH ACUTE ISCHEMIC STROKE- A RETROSPECTIVE ANALYSIS OF US HOSPITAL DATABASE

    Oct 1, 2018, 00:00

  • PGI15 - HEALTHCARE RESOURCE UTILIZATION (HCRU) IN METASTATIC OR UNRESECTABLE GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER PATIENTS RECEIVING SECOND-LINE TREATMENT

    Oct 1, 2018, 00:00

  • PCN165 - COST-EFFECTIVENESS OF SORAFENIB FOR METASTATIC RENAL CELL CARCINOMA- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PMD44 - COST COMPARISON OF RECHARGEABLE AND NON-RECHARGEABLE DEEP BRAIN STIMULATION DEVICES IN THE NORDIC COUNTRIES

    Oct 1, 2018, 00:00

  • PMD138 - IMPACTS OF NEW EU MDRIVDR REGULATIONS FOR TURKEY

    Oct 1, 2018, 00:00

  • PND11 - INDIRECT TREATMENT COMPARISON OF AVXS-101 TO NUSINERSEN FOR THE TREATMENT OF TYPE 1 SPINAL MUSCULAR ATROPHY

    Oct 1, 2018, 00:00

  • PIN54 - COST-EFFECTIVENESS OF INTRODUCING MEN VACCINATION AGAINST HUMAN PAPILLOMAVIRUS IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PHP224 - TEMPORARY ACCESS STRUCTURES FOR INNOVATIVE, HIGH-VALUE THERAPIES- COMPARISON OF MODELS AND CONSEQUENT REIMBURSEMENT TIMELINES

    Oct 1, 2018, 00:00

  • PCN357 - SATISFACTION WITH HEALTH CARE IN LOCALLY ADVANCED HEAD AND NECK CANCER MEXICAN PATIENTS TREATED IN A THIRD LEVEL PUBLIC FACILITY

    Oct 1, 2018, 00:00

  • PCV41 - COST IMPACT ANALYSIS OF USING IMPROVE® TOOL FOR VENOUS THROMBOEMBOLISM RISK ASSESSMENT IN MEDICAL PATIENTS ADMITTED TO THE UK NHS HOSPITALS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATION

    Oct 1, 2018, 00:00

  • PRM167 - MAPPING THE SF-36 TO EQ-5D-3L IN RANDOMIZED TRIAL- THE EMOCAR STUDY (MAY 2011 – APRIL 2016)

    Oct 1, 2018, 00:00

  • PCN380 - THE PROGNOSTIC SIGNIFICANCE OF HEALTH-RELATED QUALITY OF LIFE FROM CANCER RANDOMIZED CONTROLLED TRIALS- A SYSTEMATIC EVALUATION OF THE STATISTICAL METHODS

    Oct 1, 2018, 00:00

  • PMU90 - HEALTH PROBLEMS IN HUNGARIAN ELDERLY OUTPATIENTS MEASURED BY THE EQ-5D-3L- COMPARISON WITH A POPULATION NORM FOR CENTRAL EASTERN EUROPE

    Oct 1, 2018, 00:00

  • PHP295 - REVIEW OF POSSIBLE CAUSES OF VARIATION IN NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) TECHNOLOGY APPRAISALS

    Oct 1, 2018, 00:00

  • PDB120 - EVALUATION OF HEALTH STATUS OF TYPE 2 DIABETES OUTPATIENTS RECEIVING CARE IN A TERTIARY HOSPITAL IN NIGERIA

    Oct 1, 2018, 00:00

  • PSY17 - TREATMENT REGIMENS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE INELIGIBLE FOR STEM CELL TRANSPLANTATION- A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PUK11 - ECONOMIC BURDEN OF CHRONIC KIDNEY DISEASE RELATED COMPLICATIONS AND THERAPIES IN CHINA- QUANTIFYING THE COSTS OF CARDIOVASCULAR EVENTS, BLOOD TRANSFUSION FOR ANEMIA AND DIALYSIS

    Oct 1, 2018, 00:00

  • PRS57 - ECONOMIC EVALUATION OF SINGLE INHALER TRIPLE THERAPY FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) USING THE GALAXY MODEL

    Oct 1, 2018, 00:00

  • PND48 - HEALTH AND ECONOMIC BURDEN OF PARKINSON’S DISEASE IN FINLAND

    Oct 1, 2018, 00:00

  • PGI12 - PREDICTORS OF READMISSION FOR RECURRENT CLOSTRIDIUM DIFFICILE INFECTION USING THE FRENCH HEALTH INSURANCE DATABASE

    Oct 1, 2018, 00:00

  • PRM137 - MODELING THE DISTRIBUTION OF TBEV-INFECTED TICKS IN GERMANY TO ESTIMATE TBE-INFECTIONS IN HUMANS

    Oct 1, 2018, 00:00

  • PCN170 - COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA- A CANADIAN SOCIETAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PHP320 - ANALYSIS OF HTA PROCESS ON THE BASIS OF PHARMACOECONOMIC GUIDELINES IN CENTRAL EASTERN EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PHP283 - PHARMACEUTICAL CARE IN RESIDENTIAL SOCIO-HEALTH CENTERS- OPTIMISATION OF STORAGE AND DISPENSING CIRCUIT

    Oct 1, 2018, 00:00

  • PCV80 - COST-EFFECTIVENESS OF NOACS IN PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PIN101 - ACUTE GASTROENTERITIS HOSPITALIZATIONS- EXPLORING SPATIO-TEMPORAL PATTERNS AND SELF-FINANCED ROTAVIRUS VACCINATION EFFECT

    Oct 1, 2018, 00:00

  • PMU69 - DESCRIPTION OF HEALTH CARE ACTIVITY OF A NUTRITION AREA MANAGED BY A HOSPITAL PHARMACY SERVICE

    Oct 1, 2018, 00:00

  • PND56 - A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY- COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN ...

    Oct 1, 2018, 00:00

  • PRM116 - GENERAL PERCEPTIONS OF INNOVATIVE METHODS FOR SURVIVAL EXTRAPOLATION IN ONCOLOGY AMONG HTA IN EUROPE, CANADA AND AUSTRALIA

    Oct 1, 2018, 00:00

  • PCV30 - REAL WORLD EVIDENCE OF THE RISK OF STROKE OR SYSTEMIC EMBOLISM IN CHRONIC KIDNEY DISEASE PATIENTS WITH ATRIAL FIBRILLATION

    Oct 1, 2018, 00:00

  • PMH62 - DEPRESCRIBING OF BENZODIAZEPINES AMONGST THE PATIENTS OF DEPARTMENT OF PSYCHIATRY IN A TERTIARY CARE HOSPITAL, BANGALORE, KARNATAKA.

    Oct 1, 2018, 00:00

  • PHP318 - EXPERIENCE WITH EARLY DIALOGUES (ED) IN EUNETHTA JA3

    Oct 1, 2018, 00:00

  • PSY72 - COST OF ILLNESS ANALYSIS- ECONOMIC BURDEN IN DIRECT COSTS OF OBESITY-RELATED CO-MORBIDITIES – STROKE, MYOCARDIAL INFARCTION, TYPE 2 DIABETES - IN RUSSIA

    Oct 1, 2018, 00:00

  • PDB124 - PERSONALIZED DIABETES MANAGEMENT- WHAT DO PATIENTS WITH DIABETES MELLITUS PREFER?

    Oct 1, 2018, 00:00

  • PCN329 - OUTCOMES-BASED ARRANGEMENTS IN ONCOLOGY- A LANDSCAPE ANALYSIS

    Oct 1, 2018, 00:00

  • PDB9 - ASSOCIATION BETWEEN CLASS OF ANTIDIABETIC DRUGS AND INCIDENCE OF MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELITUS- A PROPORTIONAL HAZARD ANALYSIS USING DEEP LEARNING FOR RISK ADJUSTMENT

    Oct 1, 2018, 00:00

  • PSY204 - EARLY ENGAGEMENT OF THE “PATIENT VOICE” TO INFORM PATIENT REPORTED OUTCOME (PRO) MEASUREMENT IN GLOBAL PIVOTAL TREATMENT TRIAL OF CHOLANGIOCARCINOMA (CCA)

    Oct 1, 2018, 00:00

  • PHP306 - CAN GRADEPRO SUPPORT AND IMPROVE CHOICE OF OUTCOMES IN HEALTH TECHNOLOGY ASSESSMENT? REPORT ON A PILOT USE WITHIN THE EUNETHTA ASSESSMENT OF FEMTOSECOND LASER ASSISTED CATARACT SURGERY (FLACS)

    Oct 1, 2018, 00:00

  • PND123 - PATIENT AND CAREGIVER WEB-BASED SURVEY- HEALTH UTILITIES IN TUBEROUS SCLEROSIS COMPLEX (TSC) PATIENT POPULATION

    Oct 1, 2018, 00:00

  • DB1 - GLYCAEMIC CONTROL, CARDIOVASCULAR DISEASE AND MORTALITY IN TYPE 2 DIABETES (T2D) PATIENTS IN A REAL LIFE SETTING OVER TIME- POPULATION-BASED DATA FROM THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PCN71 - BUDGET IMPACT ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIA

    Oct 1, 2018, 00:00

  • PMH52 - THERAPEUTIC STRATEGIES UTILIZED IN PATIENTS TREATED FOR DEPRESSION IN AN ITALIAN REAL-WORLD SETTING, VENETO REGION.

    Oct 1, 2018, 00:00

  • PND31 - COST ANALYSIS OF BOTULINUM TOXIN A (BOTOX® AND XEOMIN®) IN REAL-WORLD CLINICAL PRACTICE

    Oct 1, 2018, 00:00

  • PHP48 - INTERNATIONAL REFERENCE PRICING OF PHARMACEUTICALS- APPLY LIBERALLY OR USE SPARINGLY?

    Oct 1, 2018, 00:00

  • PND14 - LONG-TERM EFFECTIVENESS AND CARDIOVASCULAR SAFETY OF ANTIDEMENTIA THERAPIES IN MEDICARE BENEFICIARIES NEWLY DIAGNOSED WITH ALZHEIMER’S DISEASE

    Oct 1, 2018, 00:00

  • PND10 - GENIUS RWE STUDY (FINGOLIMOD REAL WORLD EVIDENCE ITALIAN MULTICENTER OBSERVATIONAL STUDY IN MULTIPLE SCLEROSIS)PRELIMINARY RESULTS

    Oct 1, 2018, 00:00

  • PMU46 - IN-HOSPITAL ECONOMIC BURDEN OF ANASTOMOTIC LEAKAGE AFTER COLORECTAL ANASTOMOSIS SURGERY- A REAL-WORLD COST ANALYSIS

    Oct 1, 2018, 00:00

  • PRS52 - COST-MINIMIZATION ANALYSIS OF SQ® HDM SLIT-TABLET IN PATIENTS WITH HOUSE DUST MITE ALLERGIC RHINITIS WITH OR WITHOUT ALLERGIC ASTHMA IN POLAND

    Oct 1, 2018, 00:00

  • PDB92 - PHYSICIANS’ ADHERENCE TO CLINICAL PRACTICE GUIDELINES IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS ELDERLY PATIENTS. THE IMPLICA2 STUDY

    Oct 1, 2018, 00:00

  • PHP281 - THE METHODOLOGICAL DIFFERENCES OF EUROPEAN JOINT ASSESSMENT AND GERMAN HTA- AN EMPIRICAL APPROACH

    Oct 1, 2018, 00:00

  • PND64 - COST-EFFECTIVENESS OF CLADRIBINE TABLETS FOR TREATMENT OF RRMS IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PSS19 - IMPORTANCE OF THE OUT-OF-POCKET COST FOR ATOPIC DERMATITIS AFFECTED ADULTS

    Oct 1, 2018, 00:00

  • PCN215 - EMERGING TRENDS IN THE MANAGEMENT OF NSCLC PD-L1+ PATIENTS IN ITALY

    Oct 1, 2018, 00:00

  • PDB84 - HETEROGENEITY OF TREATMENT EFFECT IN THE DIABETES PREVENTION PROGRAM- HIGH BASELINE RISK OF DEVELOPING DIABETES MAY PROVIDE A PLACE FOR METFORMIN IN DIABETES PREVENTION THAT USING OVERALL SAMPLE AVERAGE COSTS AND EFFECTS CONCEALS

    Oct 1, 2018, 00:00

  • PSY82 - ANNUAL COST OF CLOTTING FACTORS IN PATIENTS WITH SEVERE (SEV) HEMOPHILIA A (HA) IN FRANCE

    Oct 1, 2018, 00:00

  • CN4 - COMPARISON OF MACHINE LEARNING ALGORITHMS FOR THE PREDICTION OF MISSING CROSS-SECTIONAL COST DATA

    Oct 1, 2018, 00:00

  • PSS44 - AN EVALUATION OF THE CURRENT TREATMENT PATHWAYS AND ASSOCIATED NHS RESOURCE USE FOR THE MANAGEMENT OF UNCONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS IN SECONDARY CARE

    Oct 1, 2018, 00:00

  • PCN369 - RELATION OF HEALTH RELATED QUALITY OF LIFE WITH INDICATORS OF NUTRITIONAL STATUS IN HEAD AND NECK CANCER PATIENTS ATTENDED IN A MEXICAN THIRD LEVEL PUBLIC FACILITY

    Oct 1, 2018, 00:00

  • PHP33 - UNDERSTANDING THE JAPANESE POLICY INITIATIVES AND THE PATIENT CHARACTERISTICS OF RARE, INTRACTABLE DISEASES

    Oct 1, 2018, 00:00

  • PRS93 - THE HEALTH-RELATED QUALITY OF LIFE BURDEN OF PEANUT ALLERGY IN ADULTS, ADOLESCENTS AND CHILDREN IN THE UK

    Oct 1, 2018, 00:00

  • PND95 - THE ECONOMIC BURDEN OF NERVE RELATED INJURIES IN SPINAL CLAIMS IN THE UK

    Oct 1, 2018, 00:00

  • PHP311 - UPTAKE OF JOINTLY PRODUCED EUNETHTA HEALTH TECHNOLOGY ASSESSMENTS- WHERE ARE WE NOW?

    Oct 1, 2018, 00:00

  • PCP26 - THE EUNETHTA COMPANION GUIDE – A REPOSITORY TO STRENGTHEN THE QUALITY OF EUNETHTA’S JOINT HTA PRODUCTION

    Oct 1, 2018, 00:00

  • PMD116 - UTILISATION AND ECONOMIC BURDEN OF FLOWABLE HEMOSTATIC AGENTS IN GERMAN HOSPITALS- A REAL-WORLD PATIENT CHART REVIEW STUDY

    Oct 1, 2018, 00:00

  • PRM60 - THE BURDEN OF OSTEOPOROSIS IN FOUR LATIN AMERICAN COUNTRIES- BRAZIL, MEXICO, COLOMBIA, AND ARGENTINA.

    Oct 1, 2018, 00:00

  • PDB85 - A 10 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) OF THE DIABETES PREVENTION PROGRAM OUTCOMES STUDY (DPP/DPPOS)- CLARIFYING THE PREVIOUS CONFUSION

    Oct 1, 2018, 00:00

  • PMS28 - SECUKINUMAB VERSUS INFLIXIMAB IN THE TREATMENT OF PSORIATIC ARTHRITIS- A COST PER RESPONDER ANALYSIS AMONG 48 WEEKS FROM A TUNISIAN PERSPECTIVE.

    Oct 1, 2018, 00:00

  • PRS79 - MODELING THE POPULATION YEARS OF LIFE SAVED BY INTRODUCING A REDUCED-RISK PRODUCT IN THE U.S. AND IN JAPAN

    Oct 1, 2018, 00:00

  • PSY57 - A COMPARISON BETWEEN ON DEMAND USAGE OF RFVIIA VS PROPHYLAXIS USE OF EMICIZUMAB IN HIGH TITER INHIBITORY HEMOPHILIA A PATIENTS IN IRAN; A COST UTILITY ANALYSIS

    Oct 1, 2018, 00:00

  • PHP361 - PIM AND EAMS- THE IMPACT OF PROMISING MEDICINE DESIGNATION IN ACHIEVING PATIENT ACCESS

    Oct 1, 2018, 00:00

  • PHP167 - COUNTRY-LEVEL COST-EFFECTIVENESS THRESHOLD- INITIAL ESTIMATES IN REPUBLIC OF BELARUS

    Oct 1, 2018, 00:00

  • PRM26 - TIME TO DETERIORATION (TTD) IN HEALTH RELATED QUALITY OF LIFE (HRQOL) IN NSCLC PATIENTS- A REVIEW OF DEFINITIONS

    Oct 1, 2018, 00:00

  • PHP279 - ASSESSMENT OF THE NICE FAST-TRACK APPRAISAL (FTA) PROCESS

    Oct 1, 2018, 00:00

  • PCV135 - NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS PRESCRIPTION MONITORING- HOW TO OPTIMIZE VIGILANCE IN STROKE PREVENTION

    Oct 1, 2018, 00:00

  • PND32 - COST COMPARISON OF MULTIPLE SCLEROSIS FIRST LINE TREATMENT WITH AVAILABLE INTERFERONS WITHIN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM

    Oct 1, 2018, 00:00

  • PMU103 - INCORPORATING PSYCHOLOGICAL CONSTRUCTS INTO PATIENT PREFERENCE STUDIES- WHICH YOU SHOULD CONSIDER INCLUDING IN YOUR NEXT STUDY?

    Oct 1, 2018, 00:00

  • PND88 - DESCRIBING REAL WORLD TREATMENT PATTERNS IN PAEDIATRIC DRAVET SYNDROME PATIENTS IN DENMARK USING ELECTRONIC MEDICAL RECORDS

    Oct 1, 2018, 00:00

  • PCN106 - ECONOMIC BURDEN OF END-OF-LIFE AGGRESSION IN LUNG CANCER PATIENTS FROM THE FRENCH HEALTH INSURER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCN148 - COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB COMPARED TO TREATMENT OPTIONS FOR ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AFTER PRIOR CHEMOTHERAPY - UPDATED RESULTS

    Oct 1, 2018, 00:00

  • PHP72 - A NEW FRENCH FINANCIAL INCENTIVE TO BOOST INSULIN AND ETANERCEPT BIOSIMILARS PRESCRIBING- SIMULATION OF ECONOMIC IMPACTS FOR THE PUBLIC HOSPITALS OF PARIS

    Oct 1, 2018, 00:00

  • PMS92 - THE CORRELATION BETWEEN MENTAL DISORDER PARAMETERS AND MEDICAL ADHERENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS

    Oct 1, 2018, 00:00

  • PHP141 - THE PRIVATE HEALTHCARE MARKET IN BRAZIL- A REVIEW OF 18 YEARS OF PROGRESS

    Oct 1, 2018, 00:00

  • PSS24 - ESTIMATION OF THE LONG-TERM POPULATION COSTS AND BENEFITS FOR FIVE DIFFERENT VARICELLA CHILDHOOD IMMUNIZATION STRATEGIES IN BULGARIA

    Oct 1, 2018, 00:00

  • PRS66 - ANALYSIS OF INDICATORS OF AVAILABILITY AND CONSUMPTION ANTIHISTAMIN PREPARATIONS IN UKRAINE IN 2017

    Oct 1, 2018, 00:00

  • PSY170 - IMPACT OF MULTIPLE INDICATIONS ON PRICE AND ACCESS OF DRUGS FOR AUTOIMMUNE DISEASES

    Oct 1, 2018, 00:00

  • PMD54 - DRUG-COATED BALLOON THERAPY FOR TREATMENT OF CRITICAL LIMB ISCHEMIA IN FEMOROPOPLITEAL ARTERY DISEASE- ECONOMIC ANALYSIS FOR THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PMU50 - COSTS OF NEUROMONITORING - EXAMINING THE POST-OPERATIVE FINANCIAL BURDEN TO PATIENTS FOLLOWING SPINAL SURGERY

    Oct 1, 2018, 00:00

  • PCP21 - BIOSIMILARS IN THE UK – A 2018 UPDATE

    Oct 1, 2018, 00:00

  • PCN157 - COST-EFFECTIVENESS ANALYSIS OF THE USE OF COLONOSCOPY AS A SCREENING METHOD FOR COLON CANCER IN PATIENTS OVER 50 YEARS OF AGE ON MANDATORY HEALTH INSURANCE

    Oct 1, 2018, 00:00

  • PND19 - INCIDENCE OF EPILEPSY AFTER STROKES AND REAL-WORLD ANTIEPILEPTIC DRUG TREATMENT

    Oct 1, 2018, 00:00

  • PRM103 - SECONDARY USE OF EXISTING PERSONAL HEALTH DATA FOR NON-INTERVENTIONAL STUDIES IN FRANCE

    Oct 1, 2018, 00:00

  • PMU117 - MEASURING IMPROVEMENT IN HEALTH-STATUS WITH THE OXFORD PARTICIPATION AND ACTIVITIES QUESTIONNAIRE

    Oct 1, 2018, 00:00

  • PSY16 - HEALTH OUTCOME IMPROVEMENTS IN SPINAL MUSCULAR ATROPHY TYPE 1 PATIENTS WITH AVXS-101 GENE REPLACEMENT THERAPY

    Oct 1, 2018, 00:00

  • PMS98 - EFFECTIVENESS OF FALL PREVENTION PROGRAM IN PATIENTS WITH OSTEOPOROSIS

    Oct 1, 2018, 00:00

  • PIN122 - INVESTIGATION OF FACILITATING FACTORS OF PARENTS’ DECISION-MAKING IN VACCINATION

    Oct 1, 2018, 00:00

  • PIH21 - BUDGET IMPACT OF A NEW INTRAUTERINE SYSTEM IN PORTUGAL

    Oct 1, 2018, 00:00

  • PHP218 - HOW HIGH CAN YOU GO? - THE IMPACT OF INDICATION EXPANSION AND MARKET COMPETITION ON DRUG PRICES IN THE EU5

    Oct 1, 2018, 00:00

  • PHP84 - INVESTIGATING USAGE OF REFERENCE COUNTRIES FOR PRICING AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINES IN CEE COUNTRIES

    Oct 1, 2018, 00:00

  • PCV100 - ANALYSIS OF DEMOGRAPHY DATA OF PATIENTS REGISTERED WITH ACUTE MYOCARDIAL INFARCTION ACCORDING TO TYPE OF INSTITUTE IN HUNGARY

    Oct 1, 2018, 00:00

  • PHP78 - PRICING AND REIMBURSEMENT REFORMS IN SPAIN – A SYSTEMATIC ANALYSIS OF NATIONAL PRICING DECISIONS BY THE CIPM

    Oct 1, 2018, 00:00

  • PHP191 - EVALUATION OF THE RENEWED LIFE REFORM PROGRAM FOR WORKERS WITH PREMORBID METABOLIC SYNDROME, OVERWEIGHT AND OBESITY IN THE AMAZONAS ASSISTANCE NETWORK OF PERUVIAN SOCIAL SECURITY

    Oct 1, 2018, 00:00

  • PRM76 - WHAT PHYSICIANS WANT- SEARCH AND EVIDENCE SOURCE TRENDS IN THE TRIP HEALTHCARE DATABASE

    Oct 1, 2018, 00:00

  • PDB72 - PLATELET-RICH PLASMA IN DIABETIC FOOT ULCERS- COST-EFFECTIVENESS ANALYSIS FOR SPAIN

    Oct 1, 2018, 00:00

  • PGI35 - ASSESSMENT OF ANTISECRETORY DRUGS CONSUMPTION IN UKRAINE IN COMPARISON WITH OTHER COUNTRIES OF THE WORLD

    Oct 1, 2018, 00:00

  • PCV42 - A PHARMACOECONOMIC ANALYSIS OF THE USE OF APIXABAN FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN RUSSIAN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

    Oct 1, 2018, 00:00

  • PCN102 - EXTRA-COST OF BRAIN METASTASES IN PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) - A FRENCH NATIONAL HOSPITAL DATABASE ANALYSIS

    Oct 1, 2018, 00:00

  • PSY120 - ECONOMIC BURDEN OF SYMPTOMATIC MULTIPLE MYELOMA ON THE ITALIAN HEALTH CARE SYSTEM- FOCUS ON THE MAIN DRIVER COSTS.

    Oct 1, 2018, 00:00

  • PRM163 - AN APPROACH TO EVALUATING THE EFFECT OF PRIORS IN NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PSY183 - SCOPE REVIEW OF ORPHAN DRUG PUBLIC POLICIES AND LEGISLATION IN LATIN AMERICA

    Oct 1, 2018, 00:00

  • PMS11 - ESTIMATING THE PREVALENCE, AND DESCRIBING THE MEDICAL HISTORY AND TREATMENT PATTERNS OF PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN GERMANY – AN APPROACH USING A CLAIMS DATABASE

    Oct 1, 2018, 00:00

  • PSY39 - QUANTIFYING WORLDWIDE EVIDENCE TO ESTIMATE THE RISK OF TRANSMITTING CREUTZFELDT-JAKOB DISEASE VIA SURGICAL PROCEDURES

    Oct 1, 2018, 00:00

  • PSY98 - COST-EFFECTIVENESS ANALYSIS OF FERRIC MALTOL VERSUS FERRIC CARBOXYMALTOSE FOR THE TREATMENT OF IRON DEFICIENCY ANAEMIA IN IBD PATIENTS IN SWEDEN AND FINLAND

    Oct 1, 2018, 00:00

  • PRM93 - SNDS, THE FRENCH NATIONWIDE CLAIMS DATABASE- A POWERFUL TOOL FOR PHARMACOECONOMY AND PHARMACOEPIDEMIOLOGY

    Oct 1, 2018, 00:00

  • PGI41 - CLINICAL CHARACTERISTICS OF BIOLOGIC TREATED CROHN’S DISEASE PATIENTS WITH AND WITHOUT PRIOR SURGERY IN EUROPEAN UNION

    Oct 1, 2018, 00:00

  • PMD63 - POTENTIAL LONG-TERM SAVINGS RESULTED FROM THE INTRODUCTION OF INVASIVE EEG MONITORING AS A PREOPERATIVE DIAGNOSTIC PROCEDURE IN EPILEPSY SURGERY IN HUNGARY

    Oct 1, 2018, 00:00

  • PMS66 - IMPROVING PATIENT AND FINANCIAL OUTCOMES IN THE NHS- EARLY ARTHRITIS SERVICE INCREASES PATIENT SATISFACTION WHILST SAVING COSTS

    Oct 1, 2018, 00:00

  • PRM181 - USE OF ARTIFICIAL INTELLIGENCE WITH DISTILLERSR SOFTWARE FOR A SYSTEMATIC LITERATURE REVIEW OF UTILITIES IN INFECTIOUS DISEASE

    Oct 1, 2018, 00:00

  • PCN121 - BSC COST IN TERMINAL CANCER PATIENTS IN KOREA

    Oct 1, 2018, 00:00

  • PSY133 - LIVES SAVED FROM REDUCTIONS IN CO-PRESCRIBING OF OPIOIDS AND BENZODIAZEPINES

    Oct 1, 2018, 00:00

  • PMD89 - COST-EFFECTIVENESS OF OXIGEN THERAPY WITH C-PAP FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNOEA SYNDROME (OSA) VERSUS THE STANDARD OF CARE IN THE MEXICAN PUBLIC HEALTH CARE SYSTEM

    Oct 1, 2018, 00:00

  • PDB83 - A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS IN NON-INSULIN ANTIDIABETIC TREATMENTS FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PSY60 - ORPHAN VERSUS ULTRA-ORPHAN DRUGS PRICES IN ENGLAND

    Oct 1, 2018, 00:00

  • PSY52 - ECONOMIC IMPACT OF IMPROVING PATIENT SAFETY USING SUGAMMADEX FOR ROUTINE REVERSAL OF NEUROMUSCULAR BLOCKADE IN SPAIN

    Oct 1, 2018, 00:00

  • PRM261 - INCORPORATION OF OBSERVATIONAL DATA INTO NETWORK META-ANALYSIS- A CASE STUDY

    Oct 1, 2018, 00:00

  • MD3 - FROM DRUG-DELIVERY DEVICE TO DISEASE MANAGEMENT TOOL- A STUDY OF PATIENT PREFERENCES FOR ENHANCED FEATURES IN NEXT GENERATION SELF-INJECTION DEVICES

    Oct 1, 2018, 00:00

  • PHP276 - A REVIEW OF THE IMPACT OF INTEGRATED SCIENTIFIC ADVICE FOR THE OPTIMISATION OF EVIDENCE GENERATION FOR HTA APPRAISALS

    Oct 1, 2018, 00:00

  • PRM273 - METHODOLOGICAL CONSIDERATIONS ON THE RECOMMENDATIONS TO CONDUCT AND REPORT SYSTEMATIC REVIEWS IN MEDICAL LITERATURE- SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PHP177 - THE USAGE OF PACKAGE CRITERIA IN DUTCH REIMBURSEMENT DECISION MAKING AND THEIR INFLUENCE ON ZIN RECOMMENDATIONS

    Oct 1, 2018, 00:00

  • PDB50 - COST OF HYPOGLYCAEMIA IN BOSNIA AND HERZEGOVINA

    Oct 1, 2018, 00:00

  • PIN16 - BUDGET IMPACT ANALYSIS OF INTRODUCING A READY-TO-USE, FULLY-LIQUID, PAEDIATRIC, HEXAVALENT VACCINE FOR CHILDHOOD IMMUNISATION IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PMD62 - ADVANCEMENT IN SELF-MONITORING OF BLOOD GLUCOSE (SMBG) TECHNOLOGY IMPROVES METABOLIC CONTROL, DIABETES MANAGEMENT AND PATIENT SATISFACTION IN PATIENTS WITH DIABETES AND HAS THE POTENTIAL FOR SUBSTANTIAL COST SAVINGS FOR THE GERMAN H ...

    Oct 1, 2018, 00:00

  • PRS82 - TREND AND FACTORS ASSOCIATED WITH PREVENTABLE HOSPITALIZATION AMONG CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS- A DECADE EXPERIENCE OF A NATIONAL HEALTH INSURANCE PROGRAM

    Oct 1, 2018, 00:00

  • PHP313 - ANALYSIS OF THE ANALYTICAL AND METHODOLOGICAL FRAMEWORK OF THE HEALTH ECONOMIC EVALUATION ASSESSMENTS DELIVERED IN FRANCE

    Oct 1, 2018, 00:00

  • PCV33 - THE RATE OF CARDIOVASCULAR EVENTS IN DIABETIC PATIENTS IN COLOMBIA

    Oct 1, 2018, 00:00

  • PHP111 - EXPLORING THE LEVELS OF UNDERSTANDING OF PERSONALIZED MEDICINE AMONGST MEDICAL STUDENTS IN SARAJEVO

    Oct 1, 2018, 00:00

  • PCN63 - REVIEW OF NICE HTA SUBMISSIONS INCLUDING MATCHING-ADJUSTED INDIRECT COMPARISONS AND SIMULATED TREATMENT COMPARISONS

    Oct 1, 2018, 00:00

  • PMU39 - PRICE ASSESSMENT OF ESSENTIAL GENERICS IN THE CITY OF YEREVAN

    Oct 1, 2018, 00:00

  • PHP140 - CURRENT CHALLENGES AND POTENTIAL SOLUTION FOR PRICING REGULATORY AND REIMBURSEMENT FRAMEWORK OF INNOVATIVE DRUGS IN EGYPT

    Oct 1, 2018, 00:00

  • PSY48 - BUDGET IMPACT ANALYSIS OF LOW-DOSE METHOXYFLURANE FOR THE TREATMENT OF MODERATE-TO-SEVERE TRAUMA PAIN IN CONSCIOUS ADULT PATIENTS IN SPAIN

    Oct 1, 2018, 00:00

  • PGI13 - REAL-LIFE BUDGET IMPACT OF DIRECT-ACTING ANTIVIRALS AGAINST HEPATITIS C VIRUS IN AN SPANISH PUBLIC HOSPITAL PHARMACY

    Oct 1, 2018, 00:00

  • PDB48 - ANNUAL COST OF ILLNESS OF ISCHEMIC STROKE IN TYPE 2 DIABETIC PATIENTS IN TURKEY

    Oct 1, 2018, 00:00

  • PND93 - THE IMPACT OF MYASTHENIA GRAVIS (MG) ON HEALTHCARE RESOURCE UTILIZATION- EMPIRICAL EVIDENCE FROM A US REGISTRY SAMPLE

    Oct 1, 2018, 00:00

  • PCV145 - A SYSTEMATIC LITERATURE REVIEW (SLR) ON HEALTH STATE UTILITIES ASSOCIATED WITH ANGINA AND REVASCULARISATION

    Oct 1, 2018, 00:00

  • PHP210 - DEVELOPMENT OF DRUG INNOVATIVNESS ASSESSMENT TOOL FOR DECISION-MAKING IN REIMBURSEMENT AND PRICING

    Oct 1, 2018, 00:00

  • PRS76 - DISEASE ADAPTATION AND PERCEIVED HEALTH STATUS- DOES IT EXIST AND CAN IT BE QUANTIFIED? INVESTIGATING EQ-5D IN SEVERE ASTHMA

    Oct 1, 2018, 00:00

  • PIN112 - HEALTH TECHNOLOGY ASSESSMENT OF THE AVAILABLE NRTI BACKBONES IN ITALY

    Oct 1, 2018, 00:00

  • PHP8 - THE ROLE OF GENERAL PRACTITIONERS IN TRAUMA CARE- VARIATION BY INJURY TYPE, REGION, PATIENT PROFILE, AND OVER TIME

    Oct 1, 2018, 00:00

  • PHP339 - MINIMALLY IMPORTANT DIFFERENCE (MID) OF EQ-5D-5L INDEX SCORE IN HONG KONG ADULTS POPULATION USING HONG KONG SCORING ALGORITHM

    Oct 1, 2018, 00:00

  • PRM55 - A NEW ANALYSIS METHODOLOGY TO FIND ATYPICAL COST PROFILES IN PATIENTS LIVING WITH HIV FROM A NATIONAL CLAIM INSURANCE DATA (SNIIRAM)

    Oct 1, 2018, 00:00

  • PSY151 - REAL-WORLD IMPACT OF HIGH CONCENTRATION NON-AVIAN HIGH MOLECULAR WEIGHT HYALURONAN ON UTILIZATION PATTERNS OF PAIN MEDICATIONS AMONG PATIENTS WITH OSTEOARTHRITIS OF KNEE

    Oct 1, 2018, 00:00

  • PRM224 - ARE POTENTIALLY AVOIDABLE HOSPITALIZATIONS EXPLAINED BY PRIMARY CARE? BEWARE OF SPATIAL HETEROGENEITY.

    Oct 1, 2018, 00:00

  • PCN190 - COST-EFFECTIVENESS OF NIVOLUMAB + IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PSS15 - BUDGET IMPACT ANALYSIS OF APREMILAST IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE

    Oct 1, 2018, 00:00

  • PCN211 - PATIENT CASE-MIX OF A TERTIARY CLINICAL CENTRE WITH PATIENTS DIAGNOSED WITH MALIGNANT MELANOMA BETWEEN 2012-2015

    Oct 1, 2018, 00:00

  • PMU94 - DEVELOPMENT OF JAPANESE PREFERENCE WEIGHT FOR THE ADULT SOCIAL CARE OUTCOMES TOOLKIT (ASCOT) SCT4

    Oct 1, 2018, 00:00

  • PCV24 - SAFETY AND EFFECTIVENESS OF CONTEMPORARY P2Y12 INHIBITORS IN EAST ASIAN PATIENTS WITH ACUTE CORONARY SYNDROMES- A NATIONWIDE POPULATION-BASED COHORT STUDY

    Oct 1, 2018, 00:00

  • PND55 - A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY- COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY ...

    Oct 1, 2018, 00:00

  • PRM92 - INITIAL DEVELOPMENT OF INTELLIGENCE ON HEALTH CARE DATA IN BRASIL- FACING THE OBSTACLES

    Oct 1, 2018, 00:00

  • PMU47 - THE ECONOMIC BURDEN OF OCCUPATIONAL INJURY AMONG FRONTLINE CONSTRUCTION WORKERS IN GHANA

    Oct 1, 2018, 00:00

  • PHP204 - VALIDATION OF A MULTICRITERIA DECISION ANALYSIS (MCDA) FRAMEWORK TO INCORPORATE THE PATIENTS’ PERSPECTIVE IN HEALTH TECHNOLOGY ASSESSMENT

    Oct 1, 2018, 00:00

  • PIN61 - COST-EFFECTIVENESS OF ONCE-DAILY DARUNAVIR CONTAINING SINGLE-TABLET REGIMEN (D/C/F/TAF) COMPARED WITH OTHER MULTI-TABLET REGIMENS CONTAINING BOOSTED PROTEASE INHIBITORS (BPIS)

    Oct 1, 2018, 00:00

  • PHP213 - A RETROSPECTIVE REVIEW OF REIMBURSEMENT DECISIONS BY THE HAUTE AUTORITÉ DE SANTÉ IN 2017 - UNDERLYING RATIONALE FOR MEDICINAL PRODUCTS WITH INSUFFICIENT ACTUAL MEDICAL BENEFIT

    Oct 1, 2018, 00:00

  • PCN349 - CAN WE APPLY THE UTILITY PREDICTION MATHEMATICAL MODEL FOR RECURRENT METASTATIC BREAST CANCER TO JAPANESE PATIENTS?

    Oct 1, 2018, 00:00

  • PMS73 - BRIGHT FUTURE FOR THE USE OF BIOSIMILAR INFLIXIMAB- EVIDENCE-BASED ANALYSIS USING HEALTHCARE CLAIM DATABASE

    Oct 1, 2018, 00:00

  • PCV47 - PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS

    Oct 1, 2018, 00:00

  • PND53 - MODEL-BASED ECONOMIC EVALUATIONS OF TREATMENTS FOR PARKINSON’S DISEASE- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMD112 - COST-UTILITY ANALYSIS OF VAGUS NERVE STIMULATION(VNS) FOR CHILDREN WITH INTRACTABLE EPILEPSY IN TAIWAN

    Oct 1, 2018, 00:00

  • PCN366 - QUALITATIVE PATIENT INTERVIEWS TO SUPPORT THE FACT HEPATOBILIARY SYMPTOM INDEX-8 AMONG PATIENTS WITH HEPATOCELLULAR CARCINOMA AND ELEVATED BASELINE ALPHA-FETOPROTEIN

    Oct 1, 2018, 00:00

  • PMH44 - CANADIAN ECONOMIC IMPACT OF IMPROVED WORKPLACE PRODUCTIVITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH VORTIOXETINE

    Oct 1, 2018, 00:00

  • PHP227 - THE CURRENT REIMBURSEMENT LANDSCAPE FOR DIGITAL HEALTH IN THE UK- HOW FAR ARE WE FROM A CENTRALISED, NATIONAL SYSTEM?

    Oct 1, 2018, 00:00

  • PSS25 - COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT VERSUS RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR EDEMA (DME) UNDER THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS)

    Oct 1, 2018, 00:00

  • PUK25 - EVALUATION OF THE RECOMMENDATIONS COMPLIANCE ON THE DIABETIC NEPHROPATHY MANAGEMENT IN FRANCE- THE ND-CRIS COHORT (2012-2017)

    Oct 1, 2018, 00:00

  • Estimating a Dutch Value Set for the Pediatric Preference-Based CHU9D Using a Discrete Choice Experiment with Duration

    Oct 1, 2018, 00:00

  • PMU43 - THE COST OF INFORMAL CARE IN HUNGARY- A POOLED ANALYSIS OF 14 CROSS-SECTIONAL STUDIES

    Oct 1, 2018, 00:00

  • PCV156 - CORRELATION OF THE DISEASE-SPECIFIC CSS/NYHA CLASSIFICATION WITH GENERIC HEALTH-RELATED QUALITY OF LIFE IN CORONARY ARTERY DISEASE PATIENTS

    Oct 1, 2018, 00:00

  • PCN183 - ROBOTIC VERSUS LAPAROSCOPIC SURGERY FOR RECTAL CANCER- A COMPARATIVE STUDY OF CLINICAL OUTCOMES AND COSTS-EFFECTIVENESS

    Oct 1, 2018, 00:00

  • PUK8 - EVALUATION OF PRESCRIBING PRACTICES AND DRUG-RELATED PROBLEMS IN CHRONIC KIDNEY DISEASE PATIENTS- A PROSPECTIVE OBSERVATIONAL STUDY

    Oct 1, 2018, 00:00

  • PSY146 - SERIOUS ADVERSE REACTIONS REPORTED FOR DRUGS INVOLVED IN LAWSUITS FILED AGAINST THE BRAZILIAN PUBLIC HEALTH SYSTEM

    Oct 1, 2018, 00:00

  • PCV22 - LIPID-LOWERING DRUG PRESCRIPTIONS IN A GROUP OF COLOMBIAN PATIENTS.

    Oct 1, 2018, 00:00

  • PDB80 - RE-ANALYSIS OF THE DIABETES PREVENTION PROGRAM 3 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) USING IDENTICAL DATA BUT PROPER METHODS QUESTIONS ITS CONCLUSIONS

    Oct 1, 2018, 00:00

  • PHP96 - TIME EFFICIENCY IN THE REGULATORY DECISION-MAKING PROCESS OF ORPHAN DRUGS

    Oct 1, 2018, 00:00

  • PRM120 - GRAPHICAL USER-FRIENDLY INTERFACE FOR COMPLEX HEALTH ECONOMIC MODELS BUILT IN R

    Oct 1, 2018, 00:00

  • PSS30 - COST EFFECTIVENESS OF DIMETHYL FUMARATE (DMF) IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS- A UK PERSPECTIVE

    Oct 1, 2018, 00:00

  • PND138 - INFORMATION SEARCHING PREFERENCES IN PEOPLE WITH MULTIPLE SCLEROSIS- THE INFOSEEK STUDY

    Oct 1, 2018, 00:00

  • PGI10 - COMPARATIVE EFFECTIVENESS OF PAN-GENOTYPIC THERAPIES FOR THE TREATMENT OF PATIENTS WITH HEPATITIS C VIRUS INFECTION IN BULGARIA

    Oct 1, 2018, 00:00

  • PCP34 - BIOSIMILARS- WHAT’S THE ISSUE?

    Oct 1, 2018, 00:00

  • PIH47 - SELF-MEDICATION PRACTICE IN PRIMARY DYSMENORRHEA AMONG MEDICAL AND PHARMACY STUDENTS IN UNAIZAH – KSA - A CROSS-SECTIONAL QUESTIONNAIRE STUDY

    Oct 1, 2018, 00:00

  • PGI46 - PSYCHOMETRIC EVALUATION OF THE DIARY FOR IRRITABLE BOWEL SYNDROME SYMPTOMS-CONSTIPATION (DIBSS-C)

    Oct 1, 2018, 00:00

  • PDB86 - COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN BULGARIA

    Oct 1, 2018, 00:00

  • PRM204 - PSYCHOMETRIC EVALUATION OF EORTC QLQ-C30 IN CUBAN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • PND116 - A THREE MONTH INTERIM ANALYSIS OF FINGOLIMOD TREATMENT ADHERENCE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UK- THE PATIENT REPORTED OUTCOMES WITH FINGOLIMOD IN LOCAL EXPERIENCE (PROFILE) STUDY

    Oct 1, 2018, 00:00

  • PRM213 - LEARNINGS FROM CONSUMER RESEARCH FOR PATIENT PREFERENCE RESEARCH

    Oct 1, 2018, 00:00

  • PHP93 - THE IMPACT OF SUPPLY CHAIN MARGINS AND VAT ON THE PRICES OF MEDICINES IN BULGARIA AND GREECE

    Oct 1, 2018, 00:00

  • PIN23 - CLINICAL AND ECONOMIC BURDEN OF INVASIVE MENINGOCOCCAL DISEASE IN FRANCE

    Oct 1, 2018, 00:00

  • PND62 - COST-EFFECTIVENESS OF CLADRIBINE TABLETS IN THE TREATMENT OF PATIENTS WITH HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PRM130 - OPEN-SOURCE SOFTWARE FOR DEVELOPING COMPUTATIONALLY EFFICIENT COST-EFFECTIVENESS MODELS TO EVALUATE SEQUENTIAL TREATMENT STRATEGIES IN ONCOLOGY

    Oct 1, 2018, 00:00

  • PCV112 - PATTERN OF USE OF ANTIHYPERTENSIVE DRUGS IN TWO EUROPEAN COUNTRIES- COMPARISON OF THE INDEX THERAPIES AND PERSISTENCE

    Oct 1, 2018, 00:00

  • PCN291 - MARKET ACCESS FOR ONCO-HEMATOLOGY MEDICINES - VALUE OF SINGLE ARM STUDIES - ANALYSIS OF FRENCH HTA OPINIONS

    Oct 1, 2018, 00:00

  • PRM8 - CLINICAL APPLICATION AND USAGE OF PATIENT REPORTED OUTCOME MEASURES IN AN ORTHOPAEDIC OUTPATIENT SETTING

    Oct 1, 2018, 00:00

  • PDB54 - ESTIMATED EVENTS AVOIDED AND COST OFFSETS ASSOCIATED WITH USING CANAGLIFLOZIN TO TREAT PATIENTS WITH TYPE TWO DIABETES MELLITUS (T2DM) WITH OR AT HIGH RISK OF DEVELOPING CARDIOVASCULAR DISEASE (CVD) IN ENGLAND

    Oct 1, 2018, 00:00

  • PIN33 - A DYNAMIC TRANSMISSION MODEL TO ESTIMATE THE PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF TRIVALENT INFLUENZA VACCINE HIGH DOSE FOR THE ELDERLY POPULATION IN ENGLAND AND WALES

    Oct 1, 2018, 00:00

  • PCN251 - DESCRIPTIVE ANALYSIS OF THE USE OF TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKAEMIA IN EUROPE, A REAL-WORLD PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRM190 - METHODS USED TO VALUE HEALTH RELATED QUALITY IN A SYSTEMATIC REVIEW OF COST-UTILITY ANALYSES IN HEART FAILURE

    Oct 1, 2018, 00:00

  • Association between Higher Generic Drug Use and Medicare Part D Star Ratings- An Observational Analysis

    Oct 1, 2018, 00:00

  • PMS43 - AN ECONOMIC VALUE FRAMEWORK TO ASSESS THE COST EFFECTIVENESS OF FRACTURE PREVENTION TREATMENTS IN PATIENTS WITH OSTEOPOROSIS AT IMMINENT RISK OF FRACTURE

    Oct 1, 2018, 00:00

  • PCN58 - MEDIAN SURVIVAL, MEAN SURVIVAL OR HAZARD RATIO- WHICH ENDPOINT IS THE MOST APPROPRIATE FOR PATIENTS, PHYSICIANS AND POLICY MAKERS?

    Oct 1, 2018, 00:00

  • PRM45 - DIRECT DATA WITHOUT DUPLICATION OF EFFORT- EXPERIENCE OF OBTAINING ELECTRONIC ROUTINE RESOURCE USE DATA DIRECTLY FROM HOSPITALS FROM THE UPSTREAM RCT.

    Oct 1, 2018, 00:00

  • PCV51 - COST ANALYSIS OF SAFETY OUTCOMES OF DABIGATRAN VS. WARFARIN IN THE SPANISH NATIONAL HEALTH SERVICE

    Oct 1, 2018, 00:00

  • PCN268 - TREATMENTS AND HEALTH CARE UTILISATION (HCU) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) FOLLOWING INITIAL PLATINUM THERAPY IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PRM272 - THE EUNETHTA TRANSFERABILITY TOOL- APPLICATION TO NOVEL TREATMENTS FOR RELAPSED REFRACTORY MULTIPLE MYELOMA IN THE IRISH HEALTHCARE SETTING

    Oct 1, 2018, 00:00

  • PMU74 - POTENTIAL COST SAVINGS BY PREVENTION OF ADVERSE DRUG EVENTS WITH A NOVEL MEDICATION REVIEW PROGRAM

    Oct 1, 2018, 00:00

  • PMH77 - ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE BY THE SF36V2 IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE GABAA RECEPTOR POSITIVE ALLOSTERIC MODULATOR SAGE-217 IN MAJOR DEPRESSIVE DISORDER

    Oct 1, 2018, 00:00

  • PCV120 - INDICATORS OF PRESCRIPTIVE APPROPRIATENESS AS A LEVER FOR PHARMACEUTICAL SUSTAINABILITY - THE CASE OF LOW MOLECULAR WEIGHT HEPARINS

    Oct 1, 2018, 00:00

  • PHP2 - CHARACTERISTICS OF DOCTOR-SHOPPERS- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PDB40 - IMPACT OF DAPAGLIFLOZIN ON REDUCING ECONOMIC BURDEN OF TYPE 2 DIABETES ENHANCEMENT PATIENT’S OUTCOMES AT COUNTRIES WITH HIGH INCIDENCE OF DIABETES EGYPT CASE

    Oct 1, 2018, 00:00

  • PCV94 - NUTILIS CLEAR® IN DYSPHAGIC ADULT STROKE PATIENTS WITH ASPIRATION OF 10–14 POINTS ON GUSS SCALE

    Oct 1, 2018, 00:00

  • PCN244 - REAL-WORLD EVIDENCE ON THE UTILISATION OF REGORAFENIB IN IRELAND

    Oct 1, 2018, 00:00

  • PHP24 - ANALYSIS OF SPANISH THERAPEUTIC POSITIONING REPORTS PUBLISHED UNTIL 2017

    Oct 1, 2018, 00:00

  • PIN73 - ECONOMIC BURDEN OF HIV/AIDS AMONG ELDERLY MEDICARE BENEFICIARIES POST MEDICARE PART D

    Oct 1, 2018, 00:00

  • PRM267 - WHAT IS DRIVING NICE-DECISION MAKING ON SINGLE-ARM TRIALS?

    Oct 1, 2018, 00:00

  • CV1 - A COST-EFFECTIVENESS ANALYSIS OF MULITI-GENE PHARMACOGENETIC TESTING IN ACUTE CORONARY SYNDROME PATIENTS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION

    Oct 1, 2018, 00:00

  • ND4 - COST-EFFECTIVENESS EVALUATION OF THE INTRA-DUODENAL CONTINUOUS LEVODOPA INFUSION IN ADVANCED AND SEVERE PARKINSON’S DISEASE

    Oct 1, 2018, 00:00

  • PCV88 - PHARMACOECONOMICS OF ALIROCUMAB IN TREATMENT OF HYPERCHOLESTEROLEMIA- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PCN39 - ESTIMATING THE MEAN PROGRESSION-FREE SURVIVAL OF NIRAPARIB, OLAPARIB AND RUCAPARIB COMPARED TO ROUTINE SURVEILLANCE FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT OVARIAN CANCER WITHOUT A BRCA MUTATION

    Oct 1, 2018, 00:00

  • PRM197 - RESPONDER DEFINITION OF THE MULTIPLE SCLEROSIS IMPACT SCALE (MSIS)-29 V2 AMONG PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS

    Oct 1, 2018, 00:00

  • PMS21 - BUDGET IMPACT MODEL OF INCLUSION OF TOFACITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN FRANCE

    Oct 1, 2018, 00:00

  • PMH63 - ACCESS TO ANTI-DEPRESSANT THERAPIES IN ENGLAND- IS THERE A POSTCODE LOTTERY?

    Oct 1, 2018, 00:00

  • PCN299 - A REVIEW OF APPRAISAL TIMELINES IN ONCOLOGY- DOES REIMBURSEMENT THROUGH THE CANCER DRUGS FUND (CDF) DELAY PATIENT ACCESS?

    Oct 1, 2018, 00:00

  • PUK31 - THE BURDEN ASSOCIATED WITH IMMUNOGLOBULIN A NEPHROPATHY(IGAN)

    Oct 1, 2018, 00:00

  • PCN158 - THE ADDED VALUE OF PERSONALIZED FOLLOW-UP FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

    Oct 1, 2018, 00:00

  • PDB22 - CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS REACHING A HIGH DAILY DOSE OF IDEGLIRA SIX MONTHS AFTER INITIATION IN A REAL-WORLD SETTING

    Oct 1, 2018, 00:00

  • PHP333 - ADDRESSING THE CHALLENGE OF CHRONICITY IN A REGION OF SPAIN. TAKING STEPS TOWARDS A PARTNERSHIP BETWEEN THE HEALTH CARE ADMINISTRATION AND THE PHARMACEUTICAL INDUSTRY

    Oct 1, 2018, 00:00

  • PMD117 - POINT-OF-CARE TESTING IN PRIMARY CARE- A SYSTEMATIC REVIEW OF TEST EVALUATIONS AND AVAILABLE EVIDENCE

    Oct 1, 2018, 00:00

  • PDB115 - IS USING MMAS-8 ALONE RELIABLE AND NONBIAS WHEN MEASURING MEDICATION ADHERENCE?

    Oct 1, 2018, 00:00

  • PCN185 - COST-EFFECTIVENESS OF NIVOLUMAB IN SECOND-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA IN ADULTS AFTER FAILURE OF PRIOR PLATINUM-CONTAINING THERAPY IN GREECE

    Oct 1, 2018, 00:00

  • PCV150 - HEALTH CARE RESOURCE USE AND QUALITY OF LIFE IN PATIENTS PRESCRIBED WITH SACUBITRIL/VALSARTAN IN PORTUGAL- A CROSS-SECTIONAL OBSERVATIONAL STUDY (PRIME STUDY)

    Oct 1, 2018, 00:00

  • PCV37 - IDENTIFICATION OF FACTORS AFFECTING READMISSIONS IN HEART FAILURE PATIENTS

    Oct 1, 2018, 00:00

  • PRS34 - COST AND DRUG UTILIZATION TRENDS IN INHALED CORTICOSTEROIDS/LONG-ACTING BETA AGONISTS (ICS/LABA) FIXED-DOSE COMBINATIONS IN SPAIN

    Oct 1, 2018, 00:00

  • PMU116 - PATIENT-REPORTED OUTCOMES IN A PILOT RANDOMIZED TRIAL OF GENOME SEQUENCING

    Oct 1, 2018, 00:00

  • PCN88 - NET IMPACT ANALYSIS OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN THE TREATMENT OF ADULTS WITH MULTIPLE MYELOMA FOR QUEBEC

    Oct 1, 2018, 00:00

  • PHP97 - NONADHERENCE TO TACROLIMUS IN ADULT LIVER AND KIDNEY TRANSPLANTATION IS ASSOCIATED WITH A HIGHER RISK OF EFFICACY FAILURE- REAL-WORLD EVIDENCE FROM ITALIAN ADMINISTRATIVE DATABASES

    Oct 1, 2018, 00:00

  • PND5 - A LITERATURE REVIEW REPORTING THE SIDE EFFECTS AND ANY RELATED CONSEQUENCES CAUSED BY CURRENT CHRONIC MYASTHENIA GRAVIS TREATMENTS

    Oct 1, 2018, 00:00

  • PCN378 - MINIMALLY IMPORTANT DIFFERENCES FOR INTERPRETING EORTC QLQ-C30 SCORES IN MELANOMA, BREAST CANCER AND HEAD AND NECK CANCER PATIENTS ON BEHALF OF THE EORTC BREAST, HEAD AND NECK, MELANOMA AND QUALITY OF LIFE GROUPS

    Oct 1, 2018, 00:00

  • PMS77 - DECLINE IN HEALTHCARE RESOURCE CONSUMPTION FOR PATIENTS WITH RHEUMATOID ARTHRITIS STARTING CERTOLIZUMAB PEGOL THERAPY IN FRANCE (THE ECLAIR STUDY)

    Oct 1, 2018, 00:00

  • PHP314 - THE RISE OF NICE ADVICE ON THE USE OF PHARMACEUTICALS, MEDICAL DEVICES AND DIGITAL HEALTH CARE IN THE NHS

    Oct 1, 2018, 00:00

  • PND58 - COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH ABOBOTULINUMTOXINA COMPARED TO BEST SUPPORTIVE CARE IN PATIENTS WITH UPPER LIMB SPASTICITY IN SWEDEN

    Oct 1, 2018, 00:00

  • PND40 - COST OF HEALTHCARE RESOURCE USE BY PATIENTS WITH MULTIPLE SCLEROSIS IN FRANCE ACCORDING TO DISEASE SEVERITY

    Oct 1, 2018, 00:00

  • HT4 - PAN-EUROPEAN HTA – WHERE WE HAVE BEEN, WHERE WE ARE GOING?

    Oct 1, 2018, 00:00

  • PSY218 - SYMPTOM AND IMPACT DISTURBANCE- FINDINGS FROM A QUALITATIVE ASSESSMENT OF PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)

    Oct 1, 2018, 00:00

  • PCV55 - ECONOMIC BURDEN OF STROKE IN GERMANY- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PSY167 - COMPARISON OF PHARMACOECONOMIC (PE) EVALUATIONS FOR DRUGS FOR RARE DISEASES (DRDS) EVALUATED BY CADTH AND NICE.

    Oct 1, 2018, 00:00

  • PMD24 - ASSOCIATION BETWEEN IOL DESIGN AND INCIDENCE OF PCO AND ND-YAG CAPSULOTOMY- A RETROSPECTIVE REAL WORLD EVIDENCE STUDY IN THE UK

    Oct 1, 2018, 00:00

  • Development of a Patient-Reported Outcome Measure for Geriatric Care- The Older Persons and Informal Caregivers Survey Short Form

    Oct 1, 2018, 00:00

  • PCN319 - RCT NOT RWE- TWO YEAR REPORT CARD FOR THE CANCER DRUGS FUND REFORMS

    Oct 1, 2018, 00:00

  • PMD131 - MEDICAL IMAGING EQUIPMENT IN ITALY- STATE OF ART OF INSTALLED BASE AND RENEWAL STRATEGIES

    Oct 1, 2018, 00:00

  • PMD48 - COSTS IN THE DIAGNOSIS OF SPANISH PATIENTS WITH SUSPECTED RHEUMATOID ARTHRITIS DEPENDS ON THE CCP ASSAY USED – A COMPARISON OF AUTOMATED CCP 2 AND CCP 3 ASSAYS

    Oct 1, 2018, 00:00

  • PCN362 - UNDERSTANDING PATIENT AND CLINICIAN PERCEPTIONS OF CELL AND GENE THERAPY IN ONCOLOGY USING QUALITATIVE ANALYSES OF SOCIAL MEDIA DATA

    Oct 1, 2018, 00:00

  • PMH76 - PATIENT REPORTED MEASURES OF DEPRESSIVE SYMPTOMS AND FATIGUE IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE GABAA RECEPTOR POSITIVE ALLOSTERIC MODULATOR SAGE-217 IN MAJOR DEPRESSIVE DISORDER

    Oct 1, 2018, 00:00

  • PIH2 - CLINICAL AND DEMOGRAPHIC RISK FACTORS AND COSTS OF SURGICAL SITE INFECTION FOLLOWING HYSTERECTOMY

    Oct 1, 2018, 00:00

  • PSY188 - USE OF MANAGED ENTRY AGREEMENTS IN INFLAMMATORY DISORDERS AMONG KEY HEALTH TECHNOLOGY ASSESSMENT AGENCIES

    Oct 1, 2018, 00:00

  • PHP169 - MCDA EVIDEM REFERENCE VALUE FRAMEWORK FOR DRUG EVALUATION AND DECISION MAKING IN SPAIN

    Oct 1, 2018, 00:00

  • PND26 - COST IMPLICATIONS OF A NOVEL WEIGHT DOSED TREATMENT FOR HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PSY203 - DESCRIPTIVE EPIDEMIOLOGY OF OBESITY IN A REAL WORLD POPULATION OF ADULTS IN THE UNITED STATES- 2010 - 2017

    Oct 1, 2018, 00:00

  • PCP33 - COULD THE US ADMINISTRATION IMPOSE DRUG PRICE RAISES IN THE EUROPEAN UNION (EU)?

    Oct 1, 2018, 00:00

  • PCN224 - TOWARDS CLINICAL ADOPTION OF REPURPOSED DRUGS IN ONCOLOGY- OVERCOMING REGULATORY AND MARKET ACCESS BARRIERS IN EUROPE

    Oct 1, 2018, 00:00

  • PMD123 - CLINICAL, PATIENT-REPORTED OUTCOME MEASURES (PROMS) AND ECONOMIC OUTCOMES ASSOCIATED WITH ENHANCED RECOVERY PROGRAMS IN ELECTIVE HIP AND KNEE SURGERY IN EUROPE, THE MIDDLE EAST AND AFRICA- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP119 - DISRUPTION IN PATIENT ACCESS TO INNOVATIVE THERAPY IN FRANCE AFTER INTERRUPTION OF NOMINATIVE TEMPORARY AUTHORISATION FOR USE

    Oct 1, 2018, 00:00

  • PND7 - AN EXPLORATORY ANALYSIS OF EFFICACY OF OCRELIZUMAB FOR MULTIPLE SCLEROSIS PATIENTS WITH INCREASED DISABILITY

    Oct 1, 2018, 00:00

  • PHP16 - CHANGE IN THE QUANTITY OF ONE-DAY SURGERY INTERVENTIONS BETWEEN 1997-2017 IN HUNGARY

    Oct 1, 2018, 00:00

  • PRM27 - PREDICTING STABILITY OUTCOMES FOR FOSTERED CHILDREN USING MACHINE LEARNING- APPLICATION OF OUTCOME RESEARCH TO SOCIAL CARE

    Oct 1, 2018, 00:00

  • PCN82 - BUDGET IMPACT ANALYSIS OF ALECTINIB FOR THE TREATMENT OF PATIENTS WITH UNTREATED ALK-REARRANGED NSCLC IN ITALY

    Oct 1, 2018, 00:00

  • PDB70 - ECONOMIC EVALUATION OF THE USE OF RECOMBINANT HUMAN EPIDERMAL GROWTH FACTOR (HEBERPROT-P®) AS AN ADJUVANT OF CONVENTIONAL THERAPY FOR THE TREATMENT OF DIABETIC FOOT ULCER

    Oct 1, 2018, 00:00

  • PRM238 - A SIMULATION STUDY ASSESSING THE USE OF PLAUSIBLY VAGUE PRIOR DISTRIBUTIONS IN A BAYESIAN META-ANALYSIS

    Oct 1, 2018, 00:00

  • PHP130 - SICK-PAY EXPENDITURES IN HUNGARY BETWEEN 2005-2016

    Oct 1, 2018, 00:00

  • PMS71 - SECULAR TRENDS IN THE INITIATION OF THERAPY IN SECONDARY FRACTURE PREVENTION IN EUROPE- A MULTI-NATIONAL STUDY INCLUDING DATA FROM DENMARK, SPAIN, AND THE UK.

    Oct 1, 2018, 00:00

  • PSY130 - THE RELATIONSHIP BETWEEN DISEASE TYPE AND CONDITIONAL OR EXCEPTIONAL APPROVAL BY EMA FOR ORPHAN DRUGS IN 2017

    Oct 1, 2018, 00:00

  • PDB73 - INDIRECT COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN COMPARED TO CANAGLIFLOZIN FOR PATIENTS WITH T2DM AND CARDIOVASCULAR DISEASE IN THE SPANISH NATIONAL HEALTH SERVICE

    Oct 1, 2018, 00:00

  • PRS37 - ECONOMIC BURDEN ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCV34 - A REVIEW ASSESSING THE INCIDENCE AND PREVALENCE OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION

    Oct 1, 2018, 00:00

  • PRS73 - THE BUDGET IMPACT OF NICOTINIC SUBSTITUTE REIMBURSEMENT

    Oct 1, 2018, 00:00

  • PSY150 - INEQUITY OF ORPHAN DRUGS PRICES IN EUROPE

    Oct 1, 2018, 00:00

  • PRM82 - REAL WORLD EVIDENCE (RWE) FROM ITALIAN NHS-AIFA REGISTRIES

    Oct 1, 2018, 00:00

  • PSY20 - REAL WORLD TREATMENT PERSISTANCE OF GOLIMUMAB IN THE MANAGEMENT OF IMMUNE-MEDIATED RHEUMATIC DISEASES (IMRDS) IN EUROPE- A SYSTEMATIC LITERATURE REVIEW (SLR)

    Oct 1, 2018, 00:00

  • PSS73 - IMPACT OF CENEGERMIN ON THE QUALITY OF LIFE IN NEUROTROPHIC KERATOPATHY

    Oct 1, 2018, 00:00

  • PCP23 - DOES THE EUROPEAN UNION (EU) NEED EUROPEAN HTA OR EUROPEAN PROCUREMENT?

    Oct 1, 2018, 00:00

  • PCV61 - PRODUCTIVITY LOSS AND LOCAL INDIRECT COSTS ASSOCIATED WITH ACUTE CORONARY SYNDROME AND STROKE IN SPAIN

    Oct 1, 2018, 00:00

  • PMD104 - COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF TREATING DIABETIC FOOT ULCERS WITH URGOSTART COMPARED TO A NEUTRAL DRESSING.

    Oct 1, 2018, 00:00

  • PMS62 - COST-EFFECTIVENESS OF REDUCING ARTHRITIS FATIGUE BY CLINICAL TEAMS (RAFT) USING COGNITIVE–BEHAVIOURAL APPROACHES- A RANDOMISED CONTROLLED TRIAL

    Oct 1, 2018, 00:00

  • PHP180 - ACCESS AND VALUE OF HEALTHCARE INNOVATION IN LATIN AMERICA

    Oct 1, 2018, 00:00

  • PCN86 - VALIDATION OF THE IMPACT OF TREATMENT EVOLUTION IN NON-SMALL CELL LUNG CANCER (NSCLC) MODEL (ITEN)- A DISCRETE EVENT PATIENT SIMULATION

    Oct 1, 2018, 00:00

  • PRM140 - UTILIZING ADVANCED DATA ANALYSIS AND VISUALIZATION, POWERED BY ARTIFICIAL INTELLIGENCE, TO ANALYZE PRICE MIGRATION DATA FOR ONCOLOGY PRODUCTS

    Oct 1, 2018, 00:00

  • PSY148 - PRIMARY NON-ADHERENCE AMONG NEWLY DIAGNOSED RHEUMATOID ARTHRITIS PATIENTS

    Oct 1, 2018, 00:00

  • PCV14 - TREATMENT EFFECT OF PHARMACEUTICAL CARE FOR HYPERTENSIVE PATIENTS IN PRIMARY CARE- A SYSTEMATIC REVIEW AND META-ANALYSES

    Oct 1, 2018, 00:00

  • PMU62 - ECONOMIC EVALUATION OF MESALAZINE 4G (SALOFALK®) IN THE TREATMENT OF PATIENTS WITH ULCERATIVE COLITIS LOCATED IN THE RECTUM AND SIGMOID

    Oct 1, 2018, 00:00

  • PMD118 - SEROLOGY TESTING IN SCHOOL-AGED CHILDREN WITH ASTHMA, IN THE UK, COULD LEAD TO SUBSTANTIAL COST SAVINGS FOR THE NHS- A POPULATION-BASED SIMULATION STUDY

    Oct 1, 2018, 00:00

  • PRM6 - INCREASED RISK OF CUTANEOUS ADVERSE DRUG REACTION AMONG OLDER ADULTS EXPOSED TO POLYPHARMACY

    Oct 1, 2018, 00:00

  • PSY121 - RELATIVE VALUE ASSESSMENT OF TREATMENTS FOR RARE DISEASES

    Oct 1, 2018, 00:00

  • PHP221 - CONDITIONAL APPROVAL- ARE PAYERS REWARDING THESE HIGHLY NEEDED PHARMACEUTICALS?

    Oct 1, 2018, 00:00

  • PRM128 - VALIDATION AND CONCEPTUAL DESIGN OF A HEALTH ECONOMIC MODEL FOR ANAEMIA TREATMENT IN MYELODYSPLASTIC SYNDROME

    Oct 1, 2018, 00:00

  • PDB74 - IDEGLIRA VERSUS IGLARLIXI FOR PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN- A LONG-TERM COST-EFFECTIVENESS ANALYSIS IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PSY222 - HEALTH RELATED QUALITY OF LIFE (HRQOL) IN MULTIPLE MYELOMA (MM) PATIENTS IN BULGARIA

    Oct 1, 2018, 00:00

  • PRM185 - COMPARISON OF THE MEASUREMENT PROPERTIES OF THE EQ-5D-5L AND EQ-5D-3L IN PATIENTS WITH CROHN’S DISEASE

    Oct 1, 2018, 00:00

  • PHP344 - AN ECONOMIC EVALUATION OF GENERIC DRUG ENTRIES IN TURKISH PHARMACEUTICAL MARKET

    Oct 1, 2018, 00:00

  • PCN70 - ASSESSING THE BUDGET IMPACT OF INCLUDING SUNITINIB FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ARGENTINA

    Oct 1, 2018, 00:00

  • PCN267 - HEALTHCARE UTILIZATION AND ECONOMIC BURDEN ON PATIENTS WITH BLADDER CANCER IN THE US DEPARTMENT OF DEFENSE POPULATION

    Oct 1, 2018, 00:00

  • PMU24 - WHICH MODEL(S) ARE USED TO ASSESS INDIVIDUAL-LEVEL SURROGACY IN ONCOLOGY USING KENDALL’S TAU? A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PUK39 - A CRITICAL APPRAISAL OF THE PRINCIPAL GUIDELINES FOR NEUROGENIC LOWER URINARY TRACT DYSFUNCTION USING THE AGREE II INSTRUMENT

    Oct 1, 2018, 00:00

  • PIN19 - A COST COMPARISON OF TREATING CHRONIC HEPATITIS C PATIENTS WITH SOFOSBUVIR-BASED REGIMENS

    Oct 1, 2018, 00:00

  • PHP59 - MOVING FROM THE REGULATOR TO THE PAYER AND PRESCRIBER - HOW PHARMA CAN WORK BETTER TO EFFECTIVELY MANAGE EMERGING CHALLENGES TO THE COMMERCIAL SUCCESS OF INNOVATIVE NEW THERAPIES

    Oct 1, 2018, 00:00

  • PMS24 - COST MINIMIZATION ANALYSIS OF THIRD LINE RHEUMATOID ARTHRITIS DRUGS IN ECUADOR

    Oct 1, 2018, 00:00

  • PCP30 - COMPARISON REGARDING THE TRANSPARENCY OF REIMBURSEMENT DECISIONS FOR PHARMACEUTICALS USED TO TREAT DEPRESSION IN HUNGARY, ROMANIA, TURKEY AND CIS

    Oct 1, 2018, 00:00

  • PHP76 - ANALYSIS OF APPROVAL TIMING FOR 89 NEW DRUGS IN ITALY FROM JANUARY 2015 TO MAY 2018

    Oct 1, 2018, 00:00

  • PSY61 - BARIATRIC SURGERY AND COSTS ASSOCIATED WITH HEALTHCARE USE AT TWO YEARS' FOLLOW-UP

    Oct 1, 2018, 00:00

  • PRM270 - IMPACT OF THE CLINICAL TRIAL DESIGN STRATEGY ON PRODUCT MARKET UPTAKE AND OVERALL COMMERCIAL SUCCESS

    Oct 1, 2018, 00:00

  • PRM42 - COST MODEL OF SWITCHING FROM ENBREL TO ETANERCEPT BIOSIMILARS, FOR NON MEDICAL REASONS, IN RHEUMATOID ARTHRITIS PATIENTS IN SPAIN

    Oct 1, 2018, 00:00

  • PCN96 - INITIAL THERAPY FOR ADVANCED PROSTATE CARCINOMA (PCA) WITH A GNRH AGONIST (GNRHA) AND ANTAGONISTS - A RETROSPECTIVE ANALYSIS OF PRESCRIPTION PATTERNS AND HOSPITAL COSTS BASED ON GERMAN GKV [GESETZLICHE KRANKENVERSICHERUNG (STATUTORY ...

    Oct 1, 2018, 00:00

  • PIN65 - BUDGET IMPACT ANALYSIS OF THE FIXED DOSE COMBINATION PHOSPHAZIDE/LAMIVUDINE ANTIRETROVIRAL DRUG FOR HIV TREATMENT IN RUSSA

    Oct 1, 2018, 00:00

  • PCN12 - COMPARATIVE ANALYSIS OF PROFILES OF STAGE IIIB/IV NSCLC PATIENTS BY TIME FROM DIAGNOSIS TO FIRST TREATMENT IN WESTERN EUROPE

    Oct 1, 2018, 00:00

  • PDB25 - PRESCRIBING PATTERN IN DIABETES MELLITUS PATIENTS IN SLOVENIA

    Oct 1, 2018, 00:00

  • PCV75 - AN UPDATED COST-EFFECTIVENESS PAIRWISE ANALYSIS OF APIXABAN AND WARFARIN FOR STROKE PREVENTION IN PATIENTS WITH NON- VALVULAR ATRIAL FIBRILLATION IN FRANCE

    Oct 1, 2018, 00:00

  • PIH18 - DIRECT COST OF UNINTENDED PREGNANCIES IN JAPAN- ESTIMATING POTENTIAL IMPACTS WITH INCREASED USE OF MODERN CONTRACEPTIVES

    Oct 1, 2018, 00:00

  • PCP60 - EVOLVING STRATEGIES FOR GENERATING, SYNTHESIZING, AND VISUALIZING REAL WORLD EVIDENCE IN RARE DISEASES

    Oct 1, 2018, 00:00

  • PHP21 - METHODOLOGY OF IDENTIFICATION OF RISK GROUPS UNDER PHARMACEUTICAL GUIDELINES IN A SPECIAL REGIME INSURER IN COLOMBIA

    Oct 1, 2018, 00:00

  • PSY49 - BUDGETARY IMPACT OF ORPHAN DRUGS IN THE CATALAN HEALTHCARE SERVICE

    Oct 1, 2018, 00:00

  • PSY35 - SYSTEMATIC LITERATURE REVIEW ON THE WORLDWIDE EPIDEMIOLOGY OF METHYLMALONIC ACIDEMIA WITH A FOCUS ON METHYLMALONYL-COA MUTASE DEFICIENCY

    Oct 1, 2018, 00:00

  • PND45 - CAREGIVER NEED ACROSS STAGES OF ALZHEIMER’S

    Oct 1, 2018, 00:00

  • PND148 - DEVELOPMENT OF A DIGITAL APP AND INNOVATIVE RECRUITMENT FOR AN INTERNATIONAL REAL-WORLD OBSERVATIONAL STUDY IN CHARCOT MARIE TOOTH DISEASE

    Oct 1, 2018, 00:00

  • PCN64 - REVIEW OF NICE HTA SUBMISSIONS INCLUDING METHODOLOGIES ADJUSTING FOR OVERALL SURVIVAL IN THE PRESENCE OF TREATMENT SWITCHING

    Oct 1, 2018, 00:00

  • PRS27 - ECONOMIC BURDEN OF IDIOPATHIC PULMONARY FIBROSIS (IPF) IN CHINA

    Oct 1, 2018, 00:00

  • PMS7 - LOSS OF QALYS ASSOCIATED WITH BIOSIMILAR DISCONTINUATION DUE TO NOCEBO EFFECT

    Oct 1, 2018, 00:00

  • PDB20 - PERSISTENCE TO LIRAGLUTIDE THERAPY IS ASSOCIATED WITH BETTER GLYCEMIC AND WEIGHT CONTROL IN PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PCN153 - COST-EFFECTIVENESS ANALYSIS OF APALUTAMIDE FOR TREATMENT IN NON- METASTASIS CASTRATION-RESISTANT PROSTATE CANCER

    Oct 1, 2018, 00:00

  • PSY1 - RISK OF LIVER ENZYME ELEVATION IN AUTOIMMUNE PATIENTS WITH DIFFERENT HEPATITIS B VIRUS INFECTION STATUS RECEIVING BIOLOGIC AGENTS

    Oct 1, 2018, 00:00

  • PCN33 - SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EVIDENCE (RWE) STUDIES FOR FIRST-LINE TREATMENTS IN ADVANCED OR METASTATIC RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PCN92 - THE EVALUATION OF THE ECONOMIC EFFICIENCY OF LENVATINIB IN COMBINATION WITH EVEROLIMUS IN RUSSIAN PATIENTS WITH DISSEMINATED RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PSY80 - THE COST OF HEALTHCARE FOR CHILDREN WITH SICKLE CELL DISEASE- AN ANALYSIS OF HEALTHCARE UTILIZATION AND EXPENDITURES IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PIN125 - A SYSTEMATIC LITERATURE REVIEW OF HEALTH STATE UTILITIES FOR HPV-RELATED DISEASES

    Oct 1, 2018, 00:00

  • PND78 - SOCIO-ECONOMIC IMPACT OF DRAVET SYNDROME IN GERMANY- A REAL-WORLD STUDY

    Oct 1, 2018, 00:00

  • PHP292 - ROADMAP FOR IMPLEMENTATION OF HEALTH TECHNOLOGY ASSESSMENT IN ROMANIA

    Oct 1, 2018, 00:00

  • PCV31 - ANTICOAGULANTS IN OLDER PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION AFTER INTRACRANIAL HEMORRHAGE

    Oct 1, 2018, 00:00

  • PND71 - A COST MINIMISATION ANALYSIS OF CLADRIBINE TABLETS VERSUS ALTERNATIVE HIGH EFFICACY TREATMENTS FOR RELAPSING MULTIPLE SCLEROSIS (RMS) IN THE UNIED KINGDOM.

    Oct 1, 2018, 00:00

  • PMD33 - BUDGET IMPACT ANALYSIS OF A DUAL-LAYER STENT RETRIEVER (DLSR) FOR THE TREATMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE (AIS) IN ENGLAND

    Oct 1, 2018, 00:00

  • PCN128 - COSTS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND FOLLICULAR LYMPHOMA (FL) – A RETROSPECTIVE ANALYSIS OF JAPANESE CLAIMS DATA

    Oct 1, 2018, 00:00

  • CN2 - PREDICTING UTILITY SCORES IN LOCALIZED PROSTATE CANCER- MAPPING FROM EPIC TO PORPUS

    Oct 1, 2018, 00:00

  • PDB76 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO LIRAGLUTIDE BASED ON CARDIOVASCULAR OUTCOME TRIALS

    Oct 1, 2018, 00:00

  • PIH15 - PREVALENCE OF DIAGNOSED UTERINE FIBROIDS AND ENDOMETRIOSIS IN THE US- DATA FROM A NATIONALLY REPRESENTATIVE POPULATION-BASED SURVEY

    Oct 1, 2018, 00:00

  • PIH3 - CLINICAL AND DEMOGRAPHIC RISK FACTORS AND COSTS OF SURGICAL SITE INFECTION AFTER CAESAREAN SECTION

    Oct 1, 2018, 00:00

  • PDB78 - ECONOMIC EVALUATION OF DAPAGLIFLOZIN AS ADD-ON TO METFORMIN FOR T2DM TREATMENT IN THE ISRAELI HEALTHCARE SETTING

    Oct 1, 2018, 00:00

  • PSY216 - THE RELATIONSHIP BETWEEN HEALTH-RELATED QUALITY OF LIFE AND CLINICAL VERSUS SELF-REPORTED BODY MASS INDEX

    Oct 1, 2018, 00:00

  • PCN3 - REAL WORLD EVIDENCE OF METASTATIC BREAST CANCER TREATMENT- A COMPARISON OF ADVERSE EFFECTS BETWEEN PALBOCICLIB TREATMENT AND ENDOCRINE THERAPY

    Oct 1, 2018, 00:00

  • PND36 - COSTS OF MULTIPLE SCLEROSIS IN DENMARK- A REGISTER BASED STUDY

    Oct 1, 2018, 00:00

  • PDB58 - REIMBURSEMENT FOR TYPE 2 DIABETES MELLITUS PATIENTS HOSPITALIZED IN A MUNICIPAL HOSPITAL IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PCN156 - PHARMACOECONOMICS OF NIMOTUZUMAB IN PATIENTS WITH HEAD AND NECK CANCER IN CUBA

    Oct 1, 2018, 00:00

  • PIN77 - DELAY BETWEEN HIV DIAGNOSIS AND TREATMENT INITIATION ACROSS THE EU5

    Oct 1, 2018, 00:00

  • PHP62 - HOME BREWED AUTOLOGOUS THERAPIES- CAN BIOPHARMA WIN THE WAR WITH DOMESTIC AUTOLOGOUS CELL GENE THERAPY MANUFACTURERS?

    Oct 1, 2018, 00:00

  • PRS97 - PATIENT REPORTED OUTCOMES IN COPD CLINICAL TRIALS- TRENDS AND GAPS

    Oct 1, 2018, 00:00

  • PCN110 - COSTS ASSOCIATED WITH TRACHEA, BRONCHUS AND LUNG CANCER IN RUSSIA IN 2016 YEAR

    Oct 1, 2018, 00:00

  • PCN182 - COST-EFFECTIVENESS RANDOMIZED STUDY OF LAPAROSCOPIC VERSUS OPEN BILATERAL INGUINAL HERNIA REPAIR

    Oct 1, 2018, 00:00

  • PCN67 - BUDGET IMPACT MODEL OF SUBCUTANEOUS RITUXIMAB COMPARED WITH INTRAVENOUS RITUXIMAB ON THE TREATMENT OF CD-20 POSITIVE NON-HODGKIN LYMPHOMA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Oct 1, 2018, 00:00

  • PCN120 - EPIDEMIOLOGY AND COSTS OF NON-SMALL CELL LUNG CANCER (NSCLC) IN AUSTRIA

    Oct 1, 2018, 00:00

  • PDB66 - INSULIN GAP IN TYPE 2 DIABETES- IS IT COST EFFECTIVE TO INTENSIFY TREATMENT? EVIDENCE FROM PORTUGAL USING REAL WORLD DATA

    Oct 1, 2018, 00:00

  • PCN355 - UTILITY IN FRENCH HEALTH-ECONOMIC OPINIONS- KEY LEARNINGS OF A RETROSPECTIVE ANALYSIS IN ONCOLOGY DRUGS

    Oct 1, 2018, 00:00

  • PHP264 - QUALITATIVE ANALYSIS OF CLINICAL TRIALS RELATED TO DIABETES REGISTERED WITH CLINICAL TRIAL REGISTRY OF INDIA

    Oct 1, 2018, 00:00

  • PMH49 - LAUNCHING LONG ACTING PRODUCTS TO TREAT OPIOID USE DISORDER- ARE PAYERS WILLING TO PAY PREMIUM PRICE?

    Oct 1, 2018, 00:00

  • PRM209 - HOW DO WE MEASURE UTILITIES OUTSIDE OF TRIALS IN RARE DISEASES?

    Oct 1, 2018, 00:00

  • PGI6 - 30-DAY MORTALITY RATES FOLLOWING HOSPITAL ADMISSION FOR ULCERATIVE COLITIS AND CLOSTRIDIUM DIFFICILE INFECTION

    Oct 1, 2018, 00:00

  • PSY153 - UNDERSTANDING PATTERNS OF 30-DAY READMISSION IN PATIENTS WITH CARDIAC AMYLOIDOSIS

    Oct 1, 2018, 00:00

  • PDB128 - COMPARISON OF PATIENT ACTIVATION LEVELS ACROSS VARIOUS CONDITIONS IN THE US AND EU5

    Oct 1, 2018, 00:00

  • PCN255 - CERVICAL AND BREAST CANCER IN KAZAKHSTAN BEFORE AND AFTER THE INTRODUCTION OF SCREENING- AN INTERRUPTED TIME SERIES ANALYSIS

    Oct 1, 2018, 00:00

  • PMD133 - SUCCESS FACTORS FOR §137H SGB V ASSESSMENT OF MEDICAL DEVICES IN GERMANY

    Oct 1, 2018, 00:00

  • PGI4 - REAL-WORLD TRENDS IN CLINICAL CHARACTERISTICS OF INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS INITIATING VEDOLIZUMAB OVER TIME IN ISRAEL

    Oct 1, 2018, 00:00

  • PMD124 - CLINICAL, PATIENT-REPORTED OUTCOME MEASURES (PROMS) AND ECONOMIC OUTCOMES ASSOCIATED WITH ENHANCED RECOVERY PROGRAMS IN BARIATRIC SURGERY IN EUROPE, THE MIDDLE EAST AND AFRICA- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP132 - CAN BLOCKCHAIN TECHNOLOGY IMPROVE THE QUALITY OF CLINICAL TRIAL EVIDENCE? – A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PND39 - MULTIPLE SCLEROSIS BURDEN OF ILLNESS STUDY FOR TURKEY

    Oct 1, 2018, 00:00

  • PMS48 - COST PER RESPONDER ANALYSIS FOLLOWING A 24-WEEK PSORIATIC ARTHRITIS TREATMENT WITH SECUKINUMAB VERSUS ETANERCEPT FROM THE PORTUGUESE PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PHP354 - THE IMPACT OF DATA PRIVACY REGULATIONS ON DRUG UTILIZATION DATA SHARING FOR INNOVATIVE PRICING ARRANGEMENTS

    Oct 1, 2018, 00:00

  • PMU5 - THE ROLE OF MULTIMORBIDITY ON EARLY RETIREMENT IN EUROPE - RESULTS FROM THE SURVEY OF HEALTH, AGEING AND RETIREMENT IN EUROPE (SHARE)

    Oct 1, 2018, 00:00

  • CN5 - COST-EFFECTIVENESS OF PEMBROLIZUMAB VERSUS STANDARD-OF-CARE CHEMOTHERAPIES FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE (≥50%) METASTATIC NON-SMALL CELL LUNG CANCER IN FRANCE

    Oct 1, 2018, 00:00

  • PCV96 - HEALTHCARE RESOURCE UTLISATION IN PATIENTS ON LIPID-LOWERING THERAPIES OUTSIDE OF WESTERN EUROPE- FINDINGS OF THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY (ICLPS)

    Oct 1, 2018, 00:00

  • PIH53 - COMPARISON OF THE EQ-5D-5L AND THE EQ-5D-3L USING INDIVIDUAL PATIENT DATA FROM REFORM TRIAL

    Oct 1, 2018, 00:00

  • PHP345 - INNOVATIVE PAYMENT MODELS FOR BREAKTHROUGH THERAPIES

    Oct 1, 2018, 00:00

  • PDB10 - MACROVASCULAR AND MICROVASCULAR COMPLICATIONS OF TYPE 2 DIABETES MELLITUS AND ITS ASSOCIATED FREQUENCY OF HOSPITAL ADMISSION

    Oct 1, 2018, 00:00

  • PCN236 - IMPLICATIONS OF THE FAST EVOLVING THERAPEUTIC LANDSCAPE ON APPROPRIATE COMPARATORS IN ONCOLOGICAL AMNOG BENEFIT ASSESSMENTS

    Oct 1, 2018, 00:00

  • PCN384 - HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ADVANCED (STAGE II-IV) OVARIAN CANCER RESISTANT OR REFRACTORY TO FRONTLINE PLATINUM-BASED THERAPY

    Oct 1, 2018, 00:00

  • PDB45 - COSTS OF PREVENTION, MONITORING AND TREATMENT OF IODINE DEFICIENCY DISORDERS IN GERMANY

    Oct 1, 2018, 00:00

  • PCN94 - COST-EFFECTIVENESS OF CABOZANTINIB VERSUS SUNITINIB OR PAZOPANIB AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN THE UK

    Oct 1, 2018, 00:00

  • PMS65 - MYOTONIC DISORDERS- ANALYSIS FROM THE FRENCH DRG-BASED INFORMATION SYSTEM (PMSI)

    Oct 1, 2018, 00:00

  • PND99 - CYSTIC FIBROSIS THERAPIES - KEY DRIVERS BEHIND DIFFERING HTA DECISIONS

    Oct 1, 2018, 00:00

  • PSS55 - COMPARATIVE EFFECTIVENESS OF INTEGRATED LOCAL TREATMENTS OF GENERALIZED PERIODONTITIS AND CHRONIC GINGIVITIS

    Oct 1, 2018, 00:00

  • PSY122 - MANAGEMENT OF POOR PROGNOSIS MULTIPLE MYELOMA PATIENTS UNDER REGULAR CLINICAL CONDITIONS IN SPAIN

    Oct 1, 2018, 00:00

  • PIN71 - ADENOVIRUS VIREMIA IS AN INDEPENDENT PREDICTOR OF PROLONGED TRANSPLANTATION HOSPITALIZATION IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS- FINDINGS FROM ADVANCE

    Oct 1, 2018, 00:00
  • «
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57 (current)
  • 58
  • 59
  • 60
  • »